Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Schaub, R. T. Articles by Hellweg, R. Search for Related Content PubMed Citation Articles by Schaub, R. T. Articles by Hellweg, R. Neuroendocrinology Geriatric Psychiatry Alzheimer's Disease

Serum Nerve Growth Factor Concentration and Its Role in the Preclinical Stage of Dementia

OBJECTIVE: Nerve growth factor is important for the development and function of the cholinergic basal forebrain. The authors examined the hypothesis that the concentration of nerve growth factor is lower than normal in the preclinical phase of neurodegenerative dementia, especially Alzheimer’s disease. METHOD: The serum nerve growth factor concentration of subjects from the Berlin Aging Study and the Berlin Memory Clinic who later developed Alzheimer’s disease were compared with those of subjects who were free of dementia and subjects who were already suffering from Alzheimer’s disease. RESULTS: There were 17 subjects in each group, matched for age and sex. The three groups differed in log-10-transformed mean nerve growth factor concentrations: 1.62 (SD=0.59) for the healthy comparison subjects, 0.92 (SD=0.30) for the subjects with preclinical dementia, and 1.44 (SD=0.61) for the subjects with Alzheimer’s disease. CONCLUSIONS: These results support the hypothesis of disturbed nerve growth factor regulation in the serum of patients with preclinical Alzheimer’s disease. Mechanisms by which these disturbances appear are unclear, but they may reflect the situation in the preclinical Alzheimer’s disease brain.

This article has been cited by other articles:

				R. Hellweg, P. Lohmann, R. Huber, A. Kuhl, and M. W. Riepe Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment Learn. Mem., January 1, 2006; 13(1): 63 - 71. [Abstract] [Full Text] [PDF]

				M. C. Jockers-ScheruBl, U. Matthies, H. Danker-Hopfe, U. E. Lang, R. Mahlberg, and R. Hellweg Chronic Cannabis Abuse Raises Nerve Growth Factor Serum Concentrations in Drug-Naive Schizophrenic Patients J Psychopharmacol, December 1, 2003; 17(4): 439 - 445. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us